Oral News and Research

RSS

Merck submits ridaforolimus MAA with EMA for treatment of metastatic soft-tissue, bone sarcomas

ARIAD Pharmaceuticals, Inc. today announced that its ridaforolimus partner, Merck, has submitted a marketing authorization application (MAA) for ridaforolimus with the European Medicines Agency.

1 Aug 2011

Accuray to showcase CyberKnife, TomoTherapy systems at AAPM/COMP meeting

Accuray Incorporated, the premier radiation oncology company, announced today that it will showcase the CyberKnife Robotic Radiosurgery System and the TomoTherapy Radiation Therapy Treatment System in the company's booths at the 2011 Joint American Association of Physicists in Medicine (AAPM)/Canadian Organization of Medical Physicists (COMP) Meeting.

1 Aug 2011

Helios Scholars Program at TGen strengthens biomedical education

Tomorrow's leaders in science and medicine graduate Friday from the biomedical summer internship program at the Translational Genomics Research Institute.

30 Jul 2011

New Aspen Dental office to open in Springdale

Patients looking for a dentist in Springdale, OH now have a new dental care provider option with the opening of a new Aspen Dental office this month. The new practice, which opens on August 4th at 25 East Kemper Road, will provide dental services that range from dentures and preventive care to general dentistry and restoration.

30 Jul 2011

New Aspen Dental office to open in N. Lakeland in August

Patients looking for a dentist in N. Lakeland, FL now have a new dental care provider option with the opening of a new Aspen Dental office this month.

30 Jul 2011

Researchers examine drug that has potential to stop Parkinson's progression

Researchers from Michigan State University's College of Human Medicine, Van Andel Research Institute and the Translational Genomics Research Institute are investigating a drug that has the potential to not only alleviate Parkinson's symptoms but also halt the disease's progression.

30 Jul 2011

Cadence confirms FDA dosing recommendations for OFIRMEV

Cadence Pharmaceuticals, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) approved dosing recommendations for OFIRMEV (acetaminophen) injection remains 4,000 mg per day for adults and adolescents weighing at least 50 kg.

29 Jul 2011

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Merck, known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2011.

29 Jul 2011

Studies reveal new set of mutations linked with head and neck cancer

Powerful new technologies that zoom in on the connections between human genes and diseases have illuminated the landscape of cancer, singling out changes in tumor DNA that drive the development of certain types of malignancies such as melanoma or ovarian cancer.

29 Jul 2011

Health law challenge inches toward Supreme Court

The Supreme Court was asked on Wednesday to hear a challenge to the health care overhaul law, raising the possibility that the justices could rule on the matter by next summer, just months before the presidential election.

29 Jul 2011

NIH selects Viamet's novel antifungal compound for inclusion in the TRND program

Viamet Pharmaceuticals, Inc. announced today that one of its novel antifungal compounds has been selected for inclusion in the National Institutes of Health's (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program.

29 Jul 2011

Sigma-Tau, Soligenix expand partnership to develop and commercialize orBec in Europe

Soligenix, Inc., a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of orBec into the European territory.

29 Jul 2011

Oral chicken interferon-alpha may significantly reduce influenza infection

Avian influenza virus is a threat to the commercial chicken industry and, with its recent rapid spread across China, has also shown the ability for transmission from chickens to humans and other mammals.

29 Jul 2011

Curis second quarter net loss increases to $4.9 million

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the second quarter ended June 30, 2011.

28 Jul 2011

Celgene reports second quarter total revenue of $1.18 billion

Celgene Corporation announced non-GAAP net income of $417 million, or non-GAAP diluted earnings per share of $0.89, for the quarter ended June 30, 2011. Non-GAAP net income for the second quarter of 2010 was $323 million, or non-GAAP diluted earnings per share of $0.69.

28 Jul 2011

Law center presses its health law challenge

"The Thomas Moore Law Center formally asked the Supreme Court Tuesday to reverse an appeals court decision upholding the health care reform law. Marking the first appeal of its kind to reach the nation's highest court, the conservative legal group continues to insist the mandate requiring all Americans to purchase health insurance is unconstitutional".

28 Jul 2011

Hip and knee replacement surgery linked to increased risk of clot development

When tennis star Serena Williams underwent emergency treatment for a pulmonary embolism earlier this year, the world's attention was drawn to this often fatal medical condition which, although surprisingly not uncommon, is unfamiliar to most men and women.

28 Jul 2011

Researchers draw on ontology to define pain

All over the world, patients with chronic pain struggle to express how they feel to the doctors and health-care providers who are trying to understand and treat them. Now, a University at Buffalo psychiatrist is attempting to help patients suffering from chronic pain and their doctors by drawing on ontology, the branch of philosophy concerned with the nature of being or existence.

28 Jul 2011

Thermo Fisher Scientific second quarter revenues increase 12% to record $2.90 billion

Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the second quarter ended July 2, 2011.

From Thermo Fisher Scientific Inc. 27 Jul 2011

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Aeterna Zentaris Inc. today announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer.

27 Jul 2011